Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Skeletal Radiology
Published in: Skeletal Radiology 6/2014

01-06-2014 | Case Report

Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET

Authors: Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung

Published in: Skeletal Radiology | Issue 6/2014

Login to get access

Abstract

Ewing’s sarcoma is a rare primary bone malignancy of small round blue cells. Treatment typically consists of neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. The disease response to chemotherapy can be followed with fluorodeoxyglucose (FDG) positron emission tomography (PET), which measures the metabolic activity of the tumor, and by magnetic resonance imaging (MRI), which measures tumor size. We present a unique case in which the tumor grew in size following neoadjuvant chemotherapy but decreased in metabolic activity, making it difficult to judge efficacy of the chemotherapy. An atypical response to chemotherapy in this case caused tumor growth due to a fibrotic reaction while viable tumor cells were eradicated. This case highlights the ability of FDG-PET scan to identify the uncommon situation in which a tumor that increased in size may have had a favorable response to chemotherapy. This possibility should be considered in similar cases in which FDG-PET scan shows diminishing metabolic activity despite tumor growth.
Literature
1.
Machado I, Traves V, Cruz J, Llombart B, Navarro S, Llombart–Bosch A. Superficial small round-cell tumors with special reference to the Ewing’s sarcoma family of tumors and the spectrum of differential diagnosis. Semin Diagn Pathol. 2013;30(1):85–94.PubMedCrossRef
2.
3.
Mahlendorf DE, Staege MS. Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol Ther. 2013 Jan 4;14(3).
4.
Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes Ewing sarcoma growth. Cancer Res. 2012;72(17):4494–503.PubMedCrossRef
5.
Vali K, Kokta V, Beaunoyer M, Fetni R, Teira P, Sartelet H. Extraosseous Ewing sarcoma with foci of neuroblastoma-like differentiation associated with EWSR1 (Ewing sarcoma breakpoint region 1)/FLI1 translocation without prior chemotherapy. Hum Pathol. 2012;43(10):1772–6.PubMedCrossRef
6.
Cantile M, Marra L, Franco R, Ascierto P, Liguori G, De Chiara A, et al. Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors. Med Oncol. 2013;30(1):412.PubMedCentralPubMedCrossRef
7.
Li X, McGee‐Lawrence ME, Decker M, Westendorf JJ. The Ewing’s sarcoma fusion protein, EWS‐ FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem. 2010;111(4):933–43.PubMedCrossRef
8.
Guo Y, Yuan F, Deng H, Wang HF, Jin XL, Xiao JC. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas. Am J Surg Pathol. 2011;35(6):799–806.PubMedCrossRef
9.
Vural C, Uluoglu O, Akyurek N, Oguz A, Karadeniz C. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing’s sarcoma family of tumors. Pathol Oncol Res. 2011;17(3):619–25.PubMedCrossRef
10.
Lavallee G, Lemarbre L, Bouchard R, Beauregard CG, Dussault R. Ewing’s sarcoma in adults. J Can Assoc Radiol. 1979;30(4):223–7.PubMed
11.
Wang CS, Yin QH, Liao JS, Lou JH, Ding XY, Zhu YB, et al. Primary diaphyseal osteosarcoma in long bones: imaging features and tumor characteristics. Eur J Radiol. 2012;81(11):3397–403.PubMedCrossRef
12.
Campanacci M, Bacci G, Boriani S, Laus M. Ewing’s sarcoma (a review of 195 cases). Ital J Orthop Traumatol. 1979;5(3):293–301.PubMed
13.
Lombardi F, Gasparini M, Gianni C, Petrillo R, Tesoro–Tess JD, Volterrani F, et al. Ewing’s sarcoma: an approach to radiological diagnosis. Tumori. 1979;65(3):389–99.PubMed
14.
Dahl I, Akerman M, Angervall L. Ewing’s sarcoma of bone. A correlative cytological and histological study of 14 cases. Acta Pathol Microbiol Immunol Scand A. 1986;94(6):363–9.PubMed
15.
Denecke T, Hundsdorfer P, Misch D, Steffen IG, Schonberger S, Furth C, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging. 2010;37(10):1842–53.PubMedCrossRef
16.
Kim DH, Kim SY, Lee HJ, Song BS, Cho JB, Lim JS, et al. Assessment of chemotherapy response using FDG-PET in pediatric bone tumors: a single institution experience. Cancer Res Treat. 2011;43(3):170–5.PubMedCentralPubMedCrossRef
17.
Cistaro A, Lopci E, Gastaldo L, Fania P, Brach Del Prever A, Fagioli F. The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer. 2012;59(7):1206–10.PubMedCrossRef
18.
Tsunezuka Y, Furusawa T, Yachi T, Kurumaya H. Rapidly growing intrathoracic extraskeletal Ewing’s sarcoma. Interact Cardiovasc Thorac Surg. 2012;14(1):117–9.PubMedCentralPubMedCrossRef
19.
Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2012 Nov 28.
20.
Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing’s sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10(1–2):126–40.PubMedCrossRef
21.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.PubMedCrossRef
22.
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22–9.PubMedCrossRef
23.
Salzer–Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe. 1983;4(3):135–41.PubMed
24.
Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad 3rd EU, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23(34):8828–34.PubMedCrossRef
25.
Sharma P, Khangembam BC, Suman KC, Singh H, Rastogi S, Khan SA, et al. Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma. Eur J Nucl Med Mol Imaging. 2013;40(7):1036–43.PubMedCrossRef
26.
Treglia G, Salsano M, Stefanelli A, Mattoli MV, Giordano A, Bonomo L. Diagnostic accuracy of (1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skelet Radiol. 2012;41(3):249–56.CrossRef
27.
Machado I, Llombart B, Calabuig‐Farinas S, Llombart‐Bosch A. Superficial Ewing’s sarcoma family of tumors: a clinicopathological study with differential diagnoses. J Cutan Pathol. 2011;38(8):636–43.PubMedCrossRef
28.
Gupta K, Pawaskar A, Basu S, Rajan MG, Asopa RV, Arora B, et al. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors. Clin Nucl Med. 2011;36(11):973–7.PubMedCrossRef
29.
Gaston LL, Di Bella C, Slavin J, Hicks RJ, Choong PF. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skelet Radiol. 2011;40(8):1007–15.CrossRef
30.
Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberlet M, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol. 2005;15(8):1658–66.PubMedCrossRef
31.
Evilevitch V, Weber WA, Tap WD, Allen‐Auerbach M, Chow K, Nelson SD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft tissue sarcomas. Clin Cancer Res. 2008;14(3):715–20.PubMedCrossRef
32.
Benz MR, Czernin J, Allen‐Auerbach MS, Tap WD, Dry SM, Elashoff D, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.PubMedCrossRef
33.
Daldrup‐Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001;177(1):229–36.PubMedCrossRef
Metadata
Title
Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
Authors
Zachary Sanford
Stanford Israelsen
Rajesh Sehgal
Felix H. Cheung
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Skeletal Radiology / Issue 6/2014
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-013-1779-0

Other articles of this Issue 6/2014

Skeletal Radiology 6/2014 Go to the issue

Review Article

Pisotriquetral joint disorders: an under-recognized cause of ulnar side wrist pain

Review Article

Imaging of radial wrist pain. Part II: pathology

Review Article

Imaging of radial wrist pain. I. Imaging modalities and anatomy

Scientific Article

Association between distal ulnar morphology and extensor carpi ulnaris tendon pathology

Browser's Notes

Browser’s notes

Case Report

Phosphaturic mesenchymal tumor: two contrasting cases